- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07297745
Studie naar Aldosteron-hybride SteRoïde voor het Bepalen van Genezende Behandeling van Primair Aldosteronisme
Studie naar Aldosteron-hybride SteRoïde voor het leiden van genezende behandeling van Primair Aldosteronisme
The goal of this project is to improve the diagnostic pathway for patients with primary aldosteronism, by validating non-invasive biomarkers coupled with routine computed tomography imaging. The aim is to reduce reliance on invasive procedures, shorten diagnostic timelines, and enhance accessibility to definitive diagnosis and treatment globally.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Primary Aldosteronism is a common but under-diagnosed condition, despite being a curable cause of secondary hypertension with significant long-term health consequences if left untreated. Once the diagnosis of primary aldosteronism is confirmed, subtype tests are required to demonstrate unilateral primary aldosteronism before curative surgery. Most patients need to undergo adrenal vein sampling, an invasive procedure performed under radiological guidance. However, this procedure is technically-challenging, with failure to cannulate both adrenal veins frequently leading to inconclusive results. Many patients worldwide may be offered surgery based on computed tomography imaging alone because of a lack of adrenal vein sampling expertise or a failed adrenal vein sampling result.
High hybrid hormones indicate a functional KCNJ5-mutant aldosterone-producing adenoma and, when coupled with computed tomography imaging, may provide a non-invasive alternative to adrenal vein sampling for identifying unilateral primary aldosteronism.
Ultimately, this trial aims to reduce the number of patients that will require an invasive adrenal vein sampling in future clinical diagnostics. This will improve access, and allow more patients to receive timely and curative treatment.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Troy H Puar, FRCP, PhD
- Telefoonnummer: 67888833
- E-mail: troy_puar@cgh.com.sg
Studie Locaties
-
-
-
Singapore, Singapore
- Werving
- National University Hospital
-
Contact:
- Ada Teo
- Telefoonnummer: +65 6908 2222
- E-mail: ada_ed_teo@nuhs.edu.sg
-
Hoofdonderzoeker:
- Ada Teo
-
Singapore, Singapore
- Werving
- Singapore General Hospital
-
Contact:
- Swee Du Soon
- Telefoonnummer: +65 6222 3322
- E-mail: swee.du.soon@singhealth.com.sg
-
Hoofdonderzoeker:
- Swee Du Soon
-
Singapore, Singapore
- Nog niet aan het werven
- Khoo Teck Puat Hospital
-
Contact:
- Niyati Jauhar
- Telefoonnummer: +65 6555 8000
- E-mail: jauhar.niyati@nhghealth.com.sg
-
Hoofdonderzoeker:
- Niyati Jauhar
-
Singapore, Singapore
- Nog niet aan het werven
- Tan Tock Seng Hospital
-
Contact:
- Lai Tian Rui Ray
- Telefoonnummer: +65 6357 3078
- E-mail: ray.tr.lai@nhghealth.com.sg
-
Hoofdonderzoeker:
- Lai Tian Rui Ray
-
Singapore, Singapore
- Werving
- Sengkang General Hospital
-
Contact:
- Matthew Chuah
- Telefoonnummer: +65 6930 5000
- E-mail: matthew.chuah@singhealth.com.sg
-
Hoofdonderzoeker:
- Matthew Chuah Bingfeng
-
-
Singapore
-
Singapore, Singapore, Singapore, 529889
- Werving
- Changi General Hospital
-
Contact:
- Troy H Puar, FRCP, PhD
- Telefoonnummer: +65 68503967
- E-mail: troy_puar@cgh.com.sg
-
Hoofdonderzoeker:
- Troy H Puar, FRCP, PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Confirmed diagnosis of primary aldosteronism according to the Endocrine Society guideline 2025.
- Willing to undergo subtype testing with adrenal vein sampling and/or molecular imaging (Positron Emission Tomography/Computed Tomography, PET/CT).
- Keen for surgical treatment if shown to have unilateral primary aldosteronism.
Exclusion Criteria:
- Inability to provide written informed consent.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Hybrid hormones
Previous studies have shown that hybrid hormones are elevated in patients with unilateral primary aldosteronism who have large, visible adenomas in their adrenal glands. These tumors harbour a somatic KCNJ5 mutation and are also most likely to be cured of hypertension after surgery. Hence, the investigators hypothesize that high hybrid hormones levels, in the presence of an adenoma on a computed tomography imaging would identify study participants who can proceed to surgery. |
Participants will have a baseline blood sample taken so the investigators can measure the adrenal steroid biomarkers 18-oxocortisol, 18-hydroxylcortisol and other steroids. The collected plasma or serum will then be analyzed in the laboratory using validated methods, such as liquid chromatography-tandem mass spectrometry (LC-MS/MS), to determine the levels of these biomarkers. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of participants with complete biochemical success after unilateral adrenalectomy for unilateral primary aldosteronism using Primary Aldosteronism Surgical Outcome (PASO) measured at least six months post-adrenalectomy.
Tijdsspanne: 6 months
|
Proportion of participants with correction of hypokalaemia and normalisation of aldosterone-renin-ratio following unilateral adrenalectomy, as per PASO criteria. |
6 months
|
|
Proportion of participants with KCNJ5-mutant aldosterone producing adenoma/nodule
Tijdsspanne: 6 months
|
Proportion of participants with histopathology and genetic confirmation of KCNJ5-mutant aldosterone producing adenoma/nodule in resected adrenals. |
6 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of participants with complete clinical success after unilateral adrenalectomy for unilateral primary aldosteronism using Primary Aldosteronism Surgical Outcome (PASO) measured at least six months post-adrenalectomy.
Tijdsspanne: 6 months
|
Proportion of participants with reduction in blood pressure and reduction anti-hypertensive medication following unilateral adrenalectomy, as per PASO criteria. |
6 months
|
|
Cost-effectiveness of using hybrid hormones coupled with computed tomography imaging versus other subtyping tests including adrenal vein sampling and/or molecular imaging in diagnosing participants with unilateral primary aldosteronism
Tijdsspanne: 6 months
|
Cost-effectiveness of the diagnostic course will be calculated by using calculated costs per quality-adjusted life years (QALYs) |
6 months
|
|
Diagnostic criteria using hybrid hormones/ steroid profiling coupled with computed tomography imaging
Tijdsspanne: 6 months
|
The criteria of hybrid hormones/ steroid profiling coupled with computed tomography imaging which offer the best sensitivity and specificity for lateralization of aldosterone-producing adenoma. |
6 months
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Troy Puar, FRCP, PhD, Changi General Hospital
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- TARGET-PA
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .